European regulators have moved a step closer to approving a single vaccine offering protection against both COVID-19 and influenza, a development that could simplify vaccination campaigns and boost immunity, particularly among older adults. The European Medicines Agency (EMA) recommended granting marketing authorization for mCombriax, a messenger RNA (mRNA) vaccine developed by Moderna, for individuals aged 50 and older. This combined vaccine represents a significant advancement in preventative medicine, offering a streamlined approach to protecting against two potentially serious respiratory illnesses.
The recommendation, issued on February 27, 2026, follows a thorough review of data from a Phase 3 clinical trial involving 8,000 participants aged 50 and above. The trial demonstrated that mCombriax elicited an immune response that was no less effective than administering separate, established vaccines – Moderna’s SPIKEVAX for COVID-19 and either FLUZONE HD or FLUARIX for influenza. This non-inferiority is a key finding, suggesting the combined vaccine can provide comparable protection without increasing the burden of multiple injections. The EMA’s assessment also considered the evolving nature of both viruses, noting that, like current COVID-19 and flu vaccines, the composition of mCombriax will need to be updated regularly to match circulating strains.
How mCombriax Works and Trial Results
mCombriax utilizes mRNA technology, a platform that has proven effective in the rapid development of COVID-19 vaccines. The vaccine targets specific strains of SARS-CoV-2, based on the EMA’s recommendations for the 2023/2024 season, and influenza viruses, aligning with the World Health Organization’s (WHO) 2023/2024 recommendations. Researchers also evaluated a similar mRNA vaccine focusing solely on influenza, finding it capable of preventing the flu and generating a sufficient immune response. This suggests the mRNA platform is well-suited for tackling both viral threats simultaneously.
Participants in the Phase 3 trial who received mCombriax experienced side effects comparable to those associated with existing COVID-19 and influenza vaccines. The most frequently reported adverse reactions – affecting more than one in ten individuals – included pain at the injection site, fatigue, muscle and joint pain, headache, chills, swollen lymph nodes, nausea, vomiting, and fever. The median time to onset of these side effects was two days, with a median duration of three days, according to the EMA’s review.
Next Steps and Potential Impact on Vaccination Strategies
The EMA’s positive recommendation is not the final step in the approval process. The agency will now forward its assessment to the European Commission, which will make the final decision regarding marketing authorization across the European Union. Once approved, individual EU member states will determine pricing and reimbursement policies, considering the vaccine’s potential role within their national healthcare systems. The availability of mCombriax will provide national authorities with an additional tool for their annual vaccination campaigns against COVID-19 and seasonal influenza.
Authorities will retain the flexibility to decide which vaccines to deploy and prioritize specific populations based on local conditions and risk assessments. The combined vaccine could potentially increase vaccination rates by simplifying the process and reducing the need for multiple appointments. This is particularly important for vulnerable populations, such as the elderly and those with underlying health conditions, who are at higher risk of severe complications from both COVID-19 and influenza.
Addressing Evolving Viral Strains
A crucial aspect of maintaining vaccine effectiveness is continuous monitoring of circulating viral strains. The EMA emphasized that, as with current influenza and COVID-19 vaccines, the composition of mCombriax will be regularly updated to ensure it provides optimal protection against the latest variants. This adaptive approach is essential in the ongoing fight against respiratory viruses.
The development of mCombriax reflects the ongoing innovation in vaccine technology and the commitment to developing more convenient and effective preventative measures. Even as the final decision rests with the European Commission, the EMA’s recommendation signals a promising step forward in protecting public health across Europe. The potential for a single shot to guard against both COVID-19 and influenza could significantly impact future vaccination strategies and reduce the burden of respiratory illness, especially as we continue to navigate a world where these viruses are likely to remain prevalent.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Stay informed about the latest developments in vaccine approvals and public health recommendations. Share this article with your network to help spread awareness about this important advancement.
